10th week of 2011 patent applcation highlights part 39 |
Patent application number | Title | Published |
20110060000 | ACRIDINE ANALOGS IN THE TREATMENT OF GLIOMAS - Disclosed are methods and compositions for treating gliomas that involve quinacrine and other acridine analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2011-03-10 |
20110060001 | THIENOPYRIDONE DERIVATIVES AS AMP- ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS - The present invention relates to compounds of formula (I) wherein R | 2011-03-10 |
20110060002 | CONGLOMERATES OF TENATOPRAZOLE POTASSIUM SALTS - The invention relates to conglomerates of tenatoprazole potassium salts of the following general formula (I), that consist of an equimolar mixture of enantiomers having R and S configurations and capable of crystallisation in the form of a conglomerate, wherein said salts are selected from tenatoprazole dehydrated potassium salt, tenatoprazole potassium dimethanolate, tenatoprazole potassium diethanolate and tenatoprazole potassium ethylene-glycolate. The invention also relates to a pharmaceutical composition containing such salt, and to the use of said salt. | 2011-03-10 |
20110060003 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT - Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject. | 2011-03-10 |
20110060004 | Imidazo-Pyridine Derivatives as Activin-Like Receptor Kinase (ALK4 or ALK5) Inhibitors - Compounds of formula (I): in free or salt or solvate form, where X, R | 2011-03-10 |
20110060005 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR - Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies and mitochondrial disorders are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject an amount of a farnesyl transferase inhibitor, wherein the amount administered is sufficient to stimulate mitophagy in said subject. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant. | 2011-03-10 |
20110060006 | Functionally Selective Alpha2C Adrenoreceptor Agonists - In its many embodiments, the present invention provides a novel class of heterocyclic derivatives as a2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the a2C adrenergic receptors using such compounds or pharmaceutical compositions. | 2011-03-10 |
20110060007 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 - The present invention relates to NIP thiazole derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions. | 2011-03-10 |
20110060008 | PHARMACEUTICAL COMPOSITION CONTAINING ACETYLCHOLINE ESTERASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF - A pharmaceutical composition for oral administration comprising donepezil or pharmaceutically acceptable salt thereof, and an effective amount of pH dependent excipient as a taste masking agent, to suppress the release of donepezil in the pH environment of the oral cavity and increase the release of donepezil in acidic environment. | 2011-03-10 |
20110060009 | Hydroxamate-Based Inhibitors of Deacetylases - The present teachings relate to compounds of Formula I: | 2011-03-10 |
20110060010 | SALTS OF 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)PIPERIDINE-2,6-DIONE AND DERIVATIVES THEREOF, OR POLYMORPHS OF SALTS, PROCESS FOR PREPARING SAME AND USE THEREOF - The present invention provides a pharmaceutically acceptable strong acid salt of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione, a solvate thereof, a process for preparing the same and use in the preparation of a medicament for treating diseases or physiological abnormities by inhibiting inflammatory factors or angiogenesis. The water-solubility of the pharmaceutically acceptable strong acid salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione is quite higher than that of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione. The present invention also provides polymorphs of a pharmaceutically acceptable strong acid salt of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and a solvate thereof. | 2011-03-10 |
20110060011 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE - The present invention relates generally to compounds represented in Formula (I), pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer. | 2011-03-10 |
20110060012 | 4-[3-(ARYLOXY)BENZYLIDENE]-3-METHYL PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS - The present invention relates to compounds of Formula (I), wherein Ar is a 5-membered heteroaryl moiety and X, Y and Z are independently N or CH; or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity. | 2011-03-10 |
20110060013 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. | 2011-03-10 |
20110060014 | Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents - The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases. | 2011-03-10 |
20110060015 | 5-[5-[2-(3,5-BIS(Trifluoromethyl)Phenyl)-2-MethylpropanoMethylpropanoylmet- hylamino]-4-(4-Fluoro-2-Methylphenyl)]-2-Pyridinyl-2-Alkyl-Prolinamide As NK1 Receptor Antagonists - The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C | 2011-03-10 |
20110060016 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient - Disclosed is a method of treatment of COPD by oral administration of roflumilast. | 2011-03-10 |
20110060017 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS - This invention relates to novel 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetyl-choline receptors. Due to their pharmacological profile, the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 2011-03-10 |
20110060018 | INSECTICIDAL N-SUBSTITUTED (2-SUBSTITUTED-1,3-THIAZOL)ALKYL SULFOXIMINES - N-Substituted (2-substituted-1,3-thiazol)alkyl sulfoximines are effective at controlling insects. | 2011-03-10 |
20110060019 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS - This invention relates to compounds of formula (I) | 2011-03-10 |
20110060020 | PROCESS FOR RELEASE OF BIOLOGICALLY ACTIVE SPECIES - A process for the release of a biologically active species comprising the steps of:
| 2011-03-10 |
20110060021 | HISTONE DEACETYLASE INHIBITORS AND USES THEREOF - Provided herein is a compound of Formula I: | 2011-03-10 |
20110060022 | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic Acid - 465 - 4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid and pharmaceutically-acceptable salts thereof and a particular crystalline form of the Agent (Form 1); their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described. | 2011-03-10 |
20110060023 | PARASITICIDAL FORMULATION - The present invention provides a parasiticidal formulation comprising: Fipronil, or a veterinarily acceptable derivative thereof; at least one C | 2011-03-10 |
20110060024 | Modulators of ATP-Binding Cassette Transporters - Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2011-03-10 |
20110060025 | 3-AMINOCARBAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING IT AND PREPARATION METHOD THEREFOR - The present invention relates to novel benzoyl derivatives of 3-aminocarbazole, to a pharmaceutical composition containing them, to a method for preparing them and to the use of such compounds for the production of a drug that is useful in the treatment or prevention of disturbances associated with the production of prostaglandin E | 2011-03-10 |
20110060026 | Indoles Active on CRTH2 Receptor - Indole derivatives having therapeutic utility are of formula (I): X is —SO | 2011-03-10 |
20110060027 | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders - The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders. | 2011-03-10 |
20110060028 | COMBINATION THERAPY - This disclosure relates to a SIRT1 polypeptide and a treatment regime that inhibits the activity of SIRT1 and including a method of diagnosis. | 2011-03-10 |
20110060029 | METHOD OF TREATING CANCER BY MODULATING EPAC - Methods of treating cancer by preventing, mitigating, and/or inhibiting cancer metastasis in tumors expressing Epac by inhibiting the activity of exchange proteins directly activated by cyclic AMP (Epac) or one or more proteins within the Epac-induced carcinoma migration pathway. | 2011-03-10 |
20110060030 | MODULATION OF APOLIPOPROTEIN C-III EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided | 2011-03-10 |
20110060031 | Compositions And Methods For Inhibiting Expression Of A Gene From The Ebola Virus - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus. | 2011-03-10 |
20110060032 | LIPID ENCAPSULATING INTERFERING RNA - The present invention provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations. | 2011-03-10 |
20110060033 | FERTILITY RESTORER GENE AND FERTILITY RESTORATION METHOD FOR CW-TYPE MALE STERILE CYTOPLASM OF RICE - Mainly provided is a technique for directly identifying the genotype at locus Rf17 based on the specific base sequence data thereof. Also provided is a technique for artificially constructing a fertility-restored line. A method of restoring the fertility of CW-type cytoplasmic male sterile rice by inhibiting or reducing the expression of a gene comprising the base sequence represented by SEQ ID NO:2 in the above-described rice, and a method for determining the presence or absence of gene Rf17, which is a fertility restorer gene for CW-type cytoplasmic male sterility, comprising identifying a single nucleotide polymorphism (SNP) in the base at the 1812 position of the base sequence represented by SEQ ID NO:1 in the rice to be examined. | 2011-03-10 |
20110060034 | CELL TRANSDIFFERENTIATION INTO BROWN ADIPOCYTES - A method for converting animal cells into brown adipose tissue cells is provided that includes transforming the animal cells using an expression vector. The expression vector includes a nucleotide sequence encoding HB-EGF operatively linked to a promoter and a nucleotide sequence encoding ADAM 12 operatively linked to a promoter. Converting animal cells to brown adipose tissue cells can be used to treat obesity or to treat cancer by converting target cells to brown adipose tissue cells. | 2011-03-10 |
20110060035 | PREVENTING AND TREATING AMYLOID-BETA DEPOSITION BY STIMULATION OF INNATE IMMUNITY - The present invention is directed to a method of preventing or reducing amyloid deposition in a subject. This method involves selecting a subject with amyloid deposits and stimulating the innate immune system of the selected subject under conditions effective to reduce the amyloid deposits. Also disclosed is a method of preventing or treating cerebral amyloidosis and Alzheimer's Disease in a subject by administering to the selected subject an agent that stimulates the innate immune system. In addition, a composition useful for the stimulation of the innate immune system of a subject exhibiting symptoms associated with amyloid deposition is disclosed. | 2011-03-10 |
20110060036 | Branched Multifunctional Nanoparticle Conjugates And Their Use - Disclosed herein are compounds and compositions including a polyglycerol nanocarrier, a therapeutic agent or imaging agent, and optionally a targeting agent. In certain aspects the disclosed compounds include biocompatible hyperbranched polymer nanocarriers. Such compounds and compositions are useful for the targeted delivery of antitumor agents and imaging agents to tumors in vivo. Methods are also disclosed for detecting and treating such tumors. | 2011-03-10 |
20110060038 | NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF - This invention is related to new nitrogenated trans-stilbene compounds, more specifically, imine, pyrrole and indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses. | 2011-03-10 |
20110060039 | COMPOSITION - A cocoa powder having a polyphenol content of at least 5% by weight, may be used to provide skin benefits by oral administration. Preferably, the cocoa powder is provided as part of a foodstuff or confectionary product, or as a cosmetic composition or supplement, The skin benefit preferably comprises a reduction in the degree of wrinkling of the skin and/or an improvement in the smoothness of the skin. | 2011-03-10 |
20110060040 | USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID - Methods of using acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof are disclosed. | 2011-03-10 |
20110060041 | METHOD OF REVERSING, PREVENTING, DELAYING OR STABILIZING SOFT TISSUE CALCIFICATION - The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung. | 2011-03-10 |
20110060042 | EXTERNAL PREPARATION FOR SKIN - The present invention provides an external preparation for skin which contains 5-aminolevulinic acids as active components and which is excellent in skin-beautifying effects such as prevention/amelioration of skin roughness, dry skin, wrinkles, sagging and flecks of skin, and improvement of turnover of corneum; and in an ameliorating effect on skin diseases such as atopic dermatitis. An external preparation for skin which contains one or more compounds selected from the group consisting of 5-aminolevulinic acid, its salt and a derivative of them; and an iron compound; as active components, is used. | 2011-03-10 |
20110060043 | INHIBITORS OF CELL PROLIFERATION AND USES THEREOF - The present invention provides novel compounds that inhibit cell proliferation and uses of these compounds for treating, ameliorating or preventing diseases, conditions or disorders benefiting from the inhibition hyperproliferation. | 2011-03-10 |
20110060044 | ALIPHATIC ACID-CONTAINING N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and an aliphatic acid. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding an aliphatic acid to said formulation. | 2011-03-10 |
20110060045 | ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES - The invention disclosed relates to the use of anti-glycation agents of formula (I), | 2011-03-10 |
20110060046 | AGENT AND FOOD FOR PREVENTING/IMPROVING FUNCTIONAL DIGESTIVE DISORDER - Provided is an agent for the prophylaxis or improvement of functional gastrointestinal disorders, which contains glutamic acid or a salt thereof other than arginine glutamate, and arginine or a salt thereof other than arginine glutamate, as active ingredients. The prophylactic or improvement agent can be produced conveniently and at low cost and is high safe and particularly effective for functional dyspepsia (FD) such as abdominal pain, heavy stomach, heartburn and the like, and upper gastrointestinal dysfunction such as esophageal reflux (GERD) and the like. | 2011-03-10 |
20110060047 | APPROACHES TO TREAT CANCER USING HB-EGF INHIBITORS - The invention provides methods for the treatment of cancer in a subject by the administration of myrsinoic acid A and/or one or more myrsinoic acid A analogs. | 2011-03-10 |
20110060048 | Removing alcohol in vivo through esterification - The present invention is pertaining to a method to chemically remove ethanol in the stomach before a significant amount of ethanol enters the blood stream. The key chemical reaction responsible for ethanol removal is esterification through a reaction between ethanol and acetic acid. Ethanol reacts with acetic acid to produce water and ethyl acetate, which is a harmless ester found in many food products. In theory, if an intoxicated individual consumes a molar quantity of vinegar similar to the amount of ethanol in the alcoholic beverage, much of the ethanol will be converted into harmless products. Low cost, practical methods for alcohol drinkers to orally take a sufficient amount of acetic components are invented. These methods include drinks containing a mixture of acetic acid and potassium hydroxide with an appropriate level of acidity. | 2011-03-10 |
20110060049 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME - This invention concerns N-(2-arylamino) aryl sulfonamide compounds which are inhibitors of MEK including crystalline polymorphic forms which exhibit a specific powder x-ray diffraction profile and/or a specific differential scanning calorimetry profile. This invention also concerns pharmaceutical compositions comprising the compounds described herein and methods of use of the compounds and compositions described herein, including the use in the treatment and/or prevention of cancer, hyperproliferative diseases and inflammatory conditions. The invention also concerns methods of making the compounds and compositions described herein. | 2011-03-10 |
20110060050 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS - The present invention relates to a compound of the formula I, Ia and Ib, and its pharmaceutically usable tautomers, salts, stereoisomers and the enantiomers, including mixtures thereof in all ratios. The present invention furthermore also relates to compounds of the formula II for the prophylaxis and/or treatment of viral diseases and/or carcinomas, in which R | 2011-03-10 |
20110060051 | PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION - The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyI)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of β-cell compensation. | 2011-03-10 |
20110060052 | Biocidal aldehyde composition for oil and gas extraction - A novel combination of a biocide (Glutaraldehyde or OPA), a surfactant, alcohol, and functional excipients for the oil and gas recovery industry. The surfactant is preferably a dual chain quaternary ammonium compound consisting of a mixture of alkyl dimethy-benzylammonium chlorides and alkyl dimethylethylbenzylammonium, that absorbs onto a surface and alters the free energy of that surface. The alcohol is preferably isopropyl alcohol. The functional excipients for the oil and gas recovery industry are a cellulose type proppant, a poloxamer wetting agent, a friction-reducing pluronic block copolymer, a drag reducing agent such as polethylene oxide, and a flocculating agent. The biocide may be OPA of the dialdehyde C | 2011-03-10 |
20110060053 | Crystalline Modifications of 6-Dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol - Crystalline modifications of (1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol, (1S,3S,6S)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol and mixtures thereof, pharmaceutical compositions and medicaments comprising these modifications, the use of these modifications as well as to a process for the enrichment of (1R,3R,6R)- or (1S,3S,6S)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol. | 2011-03-10 |
20110060054 | 2-METHYLENE-5-SUBSTITUTED-METHYLENECYCLOPENTANONE DERIVATIVES AND USE THEREOF - The invention relates to 2-methylene-5-substituted-methylenecyclopentanone derivatives of formula I, and the use thereof. The derivatives of formula I as active components are useful for preparing a medicine for the treatment and/or prevention of cancer diseases such as breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder cancer, uterus cancer, pancreatic cancer and ovary cancer. The active compounds of the invention may be used as an anticancer drug alone or used in combination with one or more other antitumor drugs. A combined therapy can be carried out by administrating each therapeutic component concurrently, subsequently or separately. | 2011-03-10 |
20110060055 | Inhibition of the Survival of Lymphoma by Cyclohexenone Compounds from Antrodia Camphorata - The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of | 2011-03-10 |
20110060056 | Inhibition of the Survival of Gastric Cancer by Cyclohexenone Compounds from Antrodia Camphorata - The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of | 2011-03-10 |
20110060057 | Inhibition of the Survival of Skin Cancer by Cyclohexenone Compounds from Antrodia Camphorata - The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3 -dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of | 2011-03-10 |
20110060058 | Inhibition of the Survival of Ovarian Cancer by Cyclohexenone Compounds from Antrodia Camphorata - The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of | 2011-03-10 |
20110060059 | Inhibition of the Survival of Bladder Cancer by Cyclohexenone Compounds from Antrodia Camphorata - The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of | 2011-03-10 |
20110060060 | Pterostilbene as a New Agonist for the Peroxisome Proliferator-Activated Receptor Alpha Isoform - Resveratrol, a stilbenoid antioxidant found in grapes, wine, peanuts and other berries, has been reported to have hypolipidemic properties. Resveratrol and its three analogs (pterostilbene, piceatannol and resveratrol trimethyl ether) were evaluated for their effects on the activation of the peroxisome proliferator-activated receptor alpha (PPARα) isoforms, a receptor shown to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPARα in H4IIEC3 cells. Pterostilbene demonstrated the highest induction of PPARα demonstrating increases of 7- and 9-14 fold relative to control. The maximal responses to pterostilbene are similar to those obtained with the hypolipidemic drug, ciprofibrate; that is, pterostilbene acts as a PPARα agonist, like that of the fibrate class, and is a more effective hypolipidemic agent than resveratrol. | 2011-03-10 |
20110060061 | MASTERBATCH COMPOSITION HAVING A HIGH POLYMER PROCESSING AID - A masterbatch composition is provided that includes a colorant, a thermoplastic carrier, a high polymer processing aid, and optionally an additive. Also provided is a method for making a masterbatch composition and a method for making a colorized polymer. | 2011-03-10 |
20110060062 | COMPOSITIONS AND METHOD FOR MAKING HOLLOW NANOPARTICLES FROM METAL SOAPS - Compositions and methods for preparing at least partially hollow nanoparticles having an outer shell comprising a one or more molecules and/or residues derived from a metal soap, where the nanoparticles each comprise a continuous inner void space that averages at least 10 percent of the volume of each of the nanoparticles. Such at least partially hollow nanoparticles can be employed in a variety of applications including, but not limited to, tire manufacturing. | 2011-03-10 |
20110060063 | METHOD FOR PRODUCING RIGID POLYURETHANE FOAM - To provide a method for producing a rigid polyurethane foam using a polymer-dispersed polyol, which has high compatibility with a polyol to be used and is excellent in the storage stability, and with which good heat insulating properties can be obtained when it is formed into a foam. | 2011-03-10 |
20110060064 | FLAME-RETARDANT, REDUCED-WEIGHT ELASTIC FLEXIBLE POLYURETHANE FOAM - A flame-retardant elastic polyurethane-soft-foam produced from a foam reaction mixture, comprising a polyol mixture, a polyisocyanate, an expandable graphite as a flame retardant, and additives. In order to reduce density while retaining long-term service properties, the polyol mixture comprises, in terms of parts by weight, from 50% to 90% of EO-based polyol, and from 50 to 10 parts by weight of standard polyol and/or filler polyol. | 2011-03-10 |
20110060065 | REMOVABLE COLOR GEL BASECOAT FOR ARTIFICIAL NAIL COATINGS AND METHODS THEREFORE - The present disclosure relates generally to compositions for natural and artificial nail coatings, and particularly, but not by way of limitation, to polymerizable compositions and adhesion-promoting basecoats polymerized therefrom. The disclosure further relates to methods of making a polymerized basecoat that are more easily removed than artificial nail enhancements and more durable and long lasting than nail polish coatings. | 2011-03-10 |
20110060066 | EMULSION COMPOSITION FOR VIBRATION DAMPING MATERIAL - The present invention provides an emulsion composition for a vibration damper, which has heating and drying properties high enough to form an excellent coating film which can exhibit excellent damping without swelling during drying by heating, and an emulsion composition for a vibration damper, which can exhibit basic performances demanded in vibration dampers, in particular, markedly superior anti-sagging even under the condition of high humidity or a thick film where the coating film may sag in conventional technologies, and thus can be useful in vibration dampers of various structures. The emulsion composition for a vibration damper includes an emulsion obtainable by emulsion polymerization of monomer components, the emulsion composition containing 0.5 to 20% by mass of a film-forming agent with a weight average molecular weight of 100 to 20000 in 100% by mass of the emulsion composition. | 2011-03-10 |
20110060067 | SILOXANE BLOCK COPOLYMER NANOPOROUS FOAMS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a foam that includes a polysiloxane block copolymer; the polysiloxane block copolymer including a first block that comprises a polysiloxane block and a second block that includes an organic polymer; the second block not containing a polysiloxane; the polysiloxane block being about 5 to about 45 repeat units; the foam having average pore sizes of less than or equal to about 100 nanometers. | 2011-03-10 |
20110060068 | RADIATION-CURABLE FORMULATIONS - The present invention relates to the use of alkoxysilane components in the presence of acid-generating photoinitiators in radiation-curable, free-radically crosslinkable formulations which in the cured state offer a particular degree of corrosion control for metallic substrates. | 2011-03-10 |
20110060069 | EC Coating and Inks Having Improved Resistance - Energy curable inks formulations are disclosed having improved resistance properties. | 2011-03-10 |
20110060070 | COATING COMPOSITION COMPRISING AN ANTIMICROBIAL CROSS-LINKER - The invention relates to a coating composition comprising an antimicrobial cross-linker, the use of said coating composition in medical applications and, in particular in a medical device and a medical device, preferably selected from catheters, endoscopes, laryngoscopes, tubes for feeding or drainage or endotracheal use or oesophageal use, comprising the coating composition. The coating composition can further comprise a hydrophilic polymer, a polyelectrolyte and a photo-initiator. | 2011-03-10 |
20110060071 | Composition of at least one vinylidene chloride copolymer - Vinylidene chloride copolymer composition characterized in that it comprises: (A) at least one vinylidene chloride copolymer which is a copolymer composed of vinylidene chloride in an amount of at least 50 wt % and of at least one comonomer at least one of which is chosen from (meth)acrylic monomers corresponding to the general formula: CH | 2011-03-10 |
20110060072 | POLYMER COMPOSITES HAVING PARTICLES WITH MIXED ORGANIC MODIFICATIONS - The present invention relates to polymer composites prepared from a host polymer and particles. Specifically, this invention is concerned with the organic modification of the particles. More specifically, the particles are organically modified with at least two organic modifiers that are different and have specific chemical and physical properties. | 2011-03-10 |
20110060073 | Methods For Fabricating Polymer-Bioceramic Composite Implantable Medical Devices - Methods relating to polymer-bioceramic composite implantable medical devices are disclosed. | 2011-03-10 |
20110060074 | Self-Repairing Concrete Used Urea-Formaldehyde Resin Polymer Micro-Capsules and Method for Fabricating Same - A self-repairing concrete includes urea-formaldehyde resin polymer micro-capsules, in which the urea-formaldehyde resin polymer micro-capsules are mixed for a fixed function of micro-cracks. The quality mixture ratio is: concrete/micro capsules/water=100:1-15:15-50. The manufacturing method is weighing a full amount of water in a container, adding urea-formaldehyde resin polymer micro-capsules, stirring, until fully dispersed microcapsules; pouring the water into the mixing container, adding the corresponding quality of cement; stirring; adding sand and gravel filling materials, conducting worksite watering, ⅓ volume for each time, vibrating, and air exhausting; until the paste filling mold. | 2011-03-10 |
20110060075 | POLYPROPYLENE RESIN COMPOSITION AND PROCESS FOR PRODUCING THE SAME - A polypropylene resin composition comprising (a) 100 parts by weight of a resin composition, which contains 51 to 99% by weight of a propylene polymer and 1 to 49% by weight of an ethylene polymer having a density of 0.85 to 0.93 g/cm | 2011-03-10 |
20110060076 | EPOXY RESINS DERIVED FROM SEED OIL BASED ALKANOLAMIDES AND A PROCESS FOR PREPARING THE SAME - An epoxy resin comprising at least one epoxy amide such as at least one of a glycidyl ether amide and a glycidyl ester amide derived from at least one seed oil based alkanolamide; wherein the seed oil based alkanolamide is derived from the reaction of (i) at least one of a fatty acid ester, a fatty acid and a fatty acid triglyceride; and (ii) at least one alkanolamine; and a process for preparing such epoxy resin. An epoxy resin composition can be prepared comprising the epoxy amide above and one or more epoxy resins other than the epoxy amide. A curable epoxy resin composition can also be made from the above epoxy resin composition which contains at least one curing agent and/or at least one curing catalyst. | 2011-03-10 |
20110060077 | Process for Manufacturing High-Performance Natural Fiber Reinforced Composites - In this patent, fibers have been successfully extracted from various natural occurring materials using a series of chemical, biological and mechanical methods. Moreover, these fibers can be conjugated onto certain polymer chains via coupling agent and chemical modification. Consequently, the thermal stability and mechanical properties of the polymers can be dramatically elevated with the incorporation of these fibers. The intended polymers include conventional plastics (epoxy resins, polyesters and polyolefins etc.), rubbers (natural rubbers and thermoplastic rubbers etc.) and biodegradable polymers. Apart from the enhancement of mechanical properties and thermal stability, the incorporation of natural fibers can reduce the production cost of the materials and meet the demand of environmental protection. | 2011-03-10 |
20110060078 | SILANE-MODIFIED POLYOLEFINS HAVING A HIGH DEGREE OF FUNCTIONALIZATION - The present invention relates to modified polyolefins having a propylene content of at least 50 ma-% and a maximum of 75 ma-%, being determined by means of | 2011-03-10 |
20110060079 | Polyamide resin composition - The present invention provides a polyamide resin composition comprising a resin of polyamide and polyacrylate mixed with a compatibilizer, an inorganic nucleating agent, a glass fiber, an antioxidant, an anti-hydrolysis agent and a lubricant in a predetermined ratio, which shows superior mechanical strength and heat resistance and improved glycol resistance and visibility maintenance, thus being useful in such a field that requires the aforementioned properties, for example in an automobile coolant reservoir tank. | 2011-03-10 |
20110060080 | POLYLACTIC ACID RESIN COMPOSITION - The present invention provides a polylactic acid resin composition, containing a polylactic acid resin and a metal hydrate surface-treated with at least one silane coupling agent selected from an amino-silane coupling agent, a mercapto-silane coupling agent and an isocyanate-silane coupling agent, wherein the content of an alkali metal component in the metal hydrate is not more than 0.2% by mass and a polylactic acid resin molded article produced by molding the polylactic acid resin composition. | 2011-03-10 |
20110060081 | COMPOUNDS SUITABLE FOR USE IN INKS AND INKS HAVING SUCH COMPOUNDS - Disclosed herein are compounds having a formula of: | 2011-03-10 |
20110060082 | POLYMER COMPOSITION AND PNEUMATIC TIRE - An object of the present invention is to provide a polymer composition that can decrease the thickness of an inner liner while maintaining air permeation resistance. The polymer composition of the present invention includes 0.1 to 50 parts by mass of an organic derivative of a clay mineral based on 100 parts by mass of a polymer mixture containing 99 to 60% by mass of a styrene-isobutylene-styrene triblock copolymer and 1 to 40% by mass of a polyamide-based polymer that contains polyamide in the molecular chain and has a Shore D hardness of 70 or less. | 2011-03-10 |
20110060083 | SPECIALIZED SILICA, RUBBER COMPOSITION CONTAINING SPECIALIZED SILICA AND PRODUCTS WITH COMPONENT THEREOF - The invention relates to allyl functionalized precipitated silica, rubber compositions containing such silica, particularly sulfur cured rubber compositions, and articles of manufacture having a component thereof such as, for example tires. The invention particularly relates to synthetic amorphous silica, particularly a precipitated silica, treated with an allyl silane, particularly to a precipitated silica containing allyl functional groups. | 2011-03-10 |
20110060084 | Polycarbonate Resin Composition With Good Light Stability and Dimensional Stability - The present invention relates to a polycarbonate resin composition that can have excellent light stability and dimensional stability, including: (A) 70 to 95 parts by weight of a thermoplastic polycarbonate resin; (B) 5 to 40 parts by weight of a thermoplastic non-crystalline polyester copolymer; (C) 5 to 50 parts by weight of titanium dioxide; (D) 0.1 to 10 parts by weight of an organic siloxane copolymer; and (E) 0.05 to 5 parts by weight of a fluorinated polyolefin-based resin. The polycarbonate resin composition can have excellent light stability and dimensional stability and also can have excellent mechanical strength without reduced impact strength and workability. The polycarbonate resin composition can be used in molded products such as LCD backlight parts requiring product dimensional stability and other parts requiring light stability. | 2011-03-10 |
20110060085 | LOW EMISSION POLYMER COMPOSITION - The present invention relates to a polymer composition comprising a polyolefin base resin comprising (A) a propylene homopolymer with a MWD of 1.5 to 5.0, and (B) an ethylene copolymer with one or more comonomers selected from alphaolefins with 4 to 12 carbon atoms, having a density of not greater than 920 kg/m | 2011-03-10 |
20110060086 | Elastomeric Copolymers, Copolymer Compositions, and Their Use in Articles - A copolymer is formed from an isoolefin having from 4 to 7 carbon atoms and an alkylstyrene. The copolymer has a substantially homogeneous compositional distribution. The copolymer has from about 8 to about 12 wt % of alkylstyrene and at least 85 wt % of isoolefin. The copolymer is preferably halogenated with about 1.1 to about 1.5 wt % of a halogen. The copolymer may in elastomeric nanocomposites. To obtain a good dispersion of the nanoclay in a formulated compound, at least one cure accelerator is selected from the group consisting of mercaptobenzothiazole disulfide, mercaptobenzothiazole, cyclohexyl benzothiazole disulfide, dibutyl thiourea, tetramethylthiuram disulfide, 4-4-dithiodimropholine, zinc dimethyldithiocarbamate, and zinc dibutylphosphorodithiate. | 2011-03-10 |
20110060087 | CARBON NANOFIBER, METHOD FOR PRODUCTION THEREOF, METHOD FOR PRODUCTION OF CARBON FIBER COMPOSITE MATERIAL USING CARBON NANOFIBER, AND CARBON FIBER COMPOSITE MATERIAL - A method of producing a carbon fiber composite material includes a first step and a second step. The first step includes oxidizing first carbon nanofibers produced by a vapor growth method to obtain second carbon nanofibers having an oxidized surface. The second step includes mixing the second carbon nanofibers into an elastomer, and uniformly dispersing the carbon nanofibers in the elastomer by applying a shear force to obtain the carbon fiber composite material. The second carbon nanofibers obtained by the first step have a surface oxygen concentration measured by X-ray photoelectron spectroscopy (XPS) of 2.6 to 4.6 atm %. | 2011-03-10 |
20110060088 | THERMOPLASTIC RESIN COMPOSITION, AND MOLDED ARTICLE - Provided is a thermoplastic resin composition, including: (A) a resin mixture including 95 to 5 mass % of (a-1) an aromatic polycarbonate resin and 5 to 95 mass % of (a-2) an aliphatic polyester; 5 to 30 parts by mass of (B) talc with respect to 100 parts by mass of the resin mixture; and 0.01 to 1 part by mass of (C) silica with respect to 100 parts by mass of the resin mixture, in which (C) the silica has an average particle diameter of 0.01 to 3 μm and a specific surface area of 50 to 400 m | 2011-03-10 |
20110060089 | THERMOPLASTIC RESIN COMPOSITION, AND MOLDED ARTICLE - Provided is a thermoplastic resin composition comprising a combination of 5 to 89.95 mass % of an aromatic polycarbonate resin (A), 5 to 60 mass % of an aliphatic polyester (B), 5 to 30 mass % of talc (C), 0.05 to 3 mass % of a functional group-containing silicone (D), and 0 to 2 mass % of polytetrafluoroethylene (E) at a total content of the components (A) to (E) of 100 mass %, in which a mass ratio of the component (D) to the component (B) is 0.003 to 0.6. The thermoplastic resin composition has remarkably improved flame retardancy and impact resistance, has excellent chemical resistance and heat resistance, and provides a molded article having an good external appearance. Also provided is a molded article obtained by using the thermoplastic resin composition. | 2011-03-10 |
20110060090 | BINDER COMBINATIONS BASED ON POLYACRYLATE DISPERIONS - Aqueous polyacrylate dispersions comprising hydrophobic co-solvents are provided. The dispersions are prepared from copolymers P) which are comprised of I) a hydroxy-functional, hydrophobic polymer containing as structural monomers Ia) (meth)acrylic acid esters having from C | 2011-03-10 |
20110060091 | DIMERCAPTAN TERMINATED POLYTHIOETHER POLYMERS AND METHODS FOR MAKING AND USING THE SAME - Dimercaptan terminated polythioether polymers are disclosed, as are methods for making and using the same. | 2011-03-10 |
20110060092 | COMPOSITION HAVING IMPROVED ADHERENCE WITH AN ADDITION-CURABLE MATERIAL AND COMPOSITE ARTICLE INCORPORATING THE COMPOSITION - A composition and composite article have improved adherence with an addition-curable material. The composition and therefore the composite article, which includes at least one substrate formed from the composition, include a resin and an additive that is incorporated into the resin. The resin is organic and polymeric and free of ethylenically unsaturated and silicon hydride functional groups. The additive is selected from the group of a fluorine-substituted organopolysiloxane, an amino-functional organopolysiloxane, an unsaturated carboxylic acid or carboxylic acid salt, and combinations thereof. Further, the additive includes a hydrosilylation reactive group present at a surface of the substrate for reaction with the addition-curable material. This improves adherence of the substrate with the addition-curable material. The substrate and the addition-curable material bond together to make the composition article. | 2011-03-10 |
20110060093 | Fire resistant, high flow poly(aryl ether sulfone) composition - Polymer composition (C) containing (i) a poly(aryl ether sulfone) material (M12) composed of a poly(biphenyl ether sulfone) (P1) and, optionally in addition, a poly(aryl ether sulfone) (P2) containing recurring units with arylene groups linked to each other via a secondary, ternary or quaternary carbon atom, and (ii) a per(halo)fluoropolymer material (M34), composed of a per(halo)fluoropolymer (P3) of which at least 2.0 wt. % of the recurring units are derived from a per(halo)fluoromonomer other than tetrafluoroethylene, and a polytetrafluoroethylene (P4). Shaped article, especially aircraft interior component, comprising the polymer composition (C). | 2011-03-10 |
20110060094 | AQUEOUS EMULSION CONTAINING ALPHA-OLEFIN/ (METH) ACRYLATE COPOLYMER AND METHOD FOR MANUFACTURING THE SAME - A method of producing an aqueous emulsion comprising a first step of kneading a mixture containing the following copolymer (A) and a polyoxyethylene polyoxypropylene block copolymer (B) by a multi-axis shearing mixer under heating to obtain a kneaded material, and a second step of dispersing the kneaded material obtained in the first step in water, and an aqueous emulsion comprising a dispersed particle containing the following copolymer (A) and a polyoxyethylene polyoxypropylene block copolymer (B) and dispersed in water, wherein the dispersed particle has a volume-based median size of 0.8 μm or less, are provided: | 2011-03-10 |
20110060095 | MODIFIED BINDERS FOR MAKING FIBERGLASS PRODUCTS - Binder compositions for making fiberglass products and methods for making and using same are provided. The binder composition can include a phenol-aldehyde resin or a mixture of Maillard reactants and one or more modifiers selected from the group consisting of a copolymer comprising one or more vinyl aromatic derived units and at least one of maleic anhydride and maleic acid; an adduct of styrene, at least one of maleic anhydride and maleic acid, and at least one of an acrylic acid and an acrylate; and one or more latexes. | 2011-03-10 |
20110060096 | CYCLIC OLEFIN RESIN COMPOSITION, AND SUBSTRATE OBTAINED FROM SAID RESIN COMPOSITION - A cyclic olefin resin composition which includes (A) 35 to 85 parts by weight of a cyclic olefin polymer having a glass transition temperature of 60 to 200° C., (B) 10 to 60 parts by weight of a flexible copolymer, prepared by polymerizing at least two monomers selected from the group consisting of an olefin compound, a diene compound and an aromatic vinyl hydrocarbon compound, and having a glass transition temperature of 0° C. or below, and (C) 5 to 55 parts by weight of a modified polyolefin. The cyclic olefin resin composition further includes, based on 100 parts by weight of total amount of the components (A), (B) and (C), (D) 0.01 to 5 parts by weight of a radical initiator and (E) 0 to 5 parts by weight of a polyfunctional compound having in its molecule two or more radically polymerizable functional groups. The composition can be used as a material for a substrate having low permittivity, low dielectric tangent, low water absorbability, and excellent heat resistance. | 2011-03-10 |
20110060097 | Dihalogen Indolocarbazole Monomers and Poly (Indolocarbazoles) - Monomers and polymers based on dihalogen indolocarbazole and poly(indolocarbazoles), and methods of making such and using the same are described, as well as organic electronic devices incorporating the same. | 2011-03-10 |
20110060098 | METHOD OF PREPARING PIGMENT COMPOSITIONS - The present invention relates to a method of preparing a pigment composition comprising the steps of combining a polymer and a pigment to form a mixture and heating the mixture to a temperature of between about 70° C. and 250° C. to form the pigment composition. The method may further comprise the step of dispersing the pigment composition in an aqueous medium to form an aqueous pigment dispersion. The pigment compositions and aqueous pigment compositions can be used in an inkjet ink composition, which is also disclosed. | 2011-03-10 |
20110060099 | COMPOSITION HAVING IMPROVED ADHERENCE WITH AN ADDITION-CURABLE MATERIAL AND COMPOSITE ARTICLE INCORPORATING THE COMPOSITION - A composition and composite article have improved adherence with an addition-curable material. The composition and therefore the composite article, which includes at least one substrate formed from the composition, include a resin and an additive that is incorporated into the resin. The resin is organic and polymeric and free of ethylenically unsaturated and silicon hydride functional groups. The additive is selected from the group of a fluorine-substituted organopolysiloxane, an amino-functional organopolysiloxane, an unsaturated carboxylic acid or carboxylic acid salt, and combinations thereof. Further, the additive includes a hydrosilylation reactive group present at a surface of the substrate for reaction with the addition-curable material. This improves adherence of the substrate with the addition-curable material. The substrate and the addition-curable material bond together to make the composition article. | 2011-03-10 |
20110060100 | MATERIAL FOR AN INKJET INK COMPOSITION AND INKJET INK COMPOSITION - A material for an inkjet ink composition, including an organic solvent; and a siloxane compound comprising at least one organic group having an optically active site and an associative site in the molecule, wherein the organic solvent satisfies the following requirements a) to c):
| 2011-03-10 |